Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7435411 | 0.96 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL11699430 | 0.95 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2151136 | 0.92 | ALDH1A1 (0.39) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL28153802 | 0.79 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL11290739 | 0.78 | TSHR (0.40) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3104107 | 0.75 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1LMNARAB9APOLB | |
| SCHEMBL4743034 | 0.74 | CYP4F2 (0.32) | SMN1; SMN2 | |
| SCHEMBL16234619 | 0.73 | CYP3A4 (0.42) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL30148463 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1606644 | 0.73 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-4876279-A | Antihypercholesterolemic compounds | MERCK & CO., INC. (US) | 1989-10-24 | — | — | US | disclosed |
| US-4766145-A | Antihypercholesterolemic compounds | MERCK & CO., INC. (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0245004-A2 | Antihypercholesterolemic compounds | MERCK & CO. INC. (US) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | SMN1; SMN2 4065/4885MEN1 4561/4885KMT2A 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.